Linked Life Data

18344626

Source:http://linkedlifedata.com/resource/pubmed/id/18344626

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2008-3-17
pubmed:abstractText
Hypertension contributes to the occurrence and progression of cardiovascular diseases. The angiotensin II type 1 receptor blocker telmisartan is reported to activate the peroxisome proliferator-activated receptor gamma and improve insulin sensitivity. We investigated the effects of telmisartan treatment on visceral fat, serum adiponectin and vascular inflammation markers in Japanese hypertensive patients. This was an open-label, non-controlled study. Twenty-eight essential hypertensive patients (22 men and 6 women; age 60.6+/-1.9 years; body mass index [BMI] 25.5+/-0.6 kg/m(2)) participated. Fat area was assessed with computerized tomography. All the subjects were started on telmisartan 40 mg/day, which was increased to 80 mg/day to achieve the blood pressure target of less than 130/80 mmHg. We assessed the visceral and subcutaneous fat areas, serum adiponectin levels, and vascular inflammation markers at baseline and 24 weeks of telmisartan treatment. There were significant reductions in visceral fat area (from 103.1+/-7.9 to 93.3+/-8.4 cm(2), p<0.01) and pulse wave velocity (from 1,706+/-52 to 1,587+/-51 cm/s, p<0.01) at 24 weeks. In contrast, significant increases in serum high-density lipoprotein cholesterol (from 5.06+/-0.15 to 5.32+/-0.13 mmol/L, p<0.05) and adiponectin levels (from 8.27+/-0.76 to 9.13+/-0.81 microg/mL, p<0.05) were observed. Also, there were reductions in the interleukin-6 level (from 2.26+/-0.27 to 1.60+/-0.14 pg/mL, p<0.01). We also conducted these investigations in male subjects alone and similar findings were obtained for all of these parameters. In conclusion, telmisartan treatment was associated with an improvement of vascular inflammation, reductions in visceral fat and increases in serum adiponectin.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0916-9636
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1205-10
pubmed:meshHeading
pubmed-meshheading:18344626-Adiponectin, pubmed-meshheading:18344626-Angiotensin II Type 1 Receptor Blockers, pubmed-meshheading:18344626-Benzimidazoles, pubmed-meshheading:18344626-Benzoates, pubmed-meshheading:18344626-Blood Pressure, pubmed-meshheading:18344626-C-Reactive Protein, pubmed-meshheading:18344626-Cholesterol, HDL, pubmed-meshheading:18344626-Female, pubmed-meshheading:18344626-Humans, pubmed-meshheading:18344626-Hypertension, pubmed-meshheading:18344626-Insulin Resistance, pubmed-meshheading:18344626-Interleukin-6, pubmed-meshheading:18344626-Intra-Abdominal Fat, pubmed-meshheading:18344626-Japan, pubmed-meshheading:18344626-Male, pubmed-meshheading:18344626-Middle Aged, pubmed-meshheading:18344626-PPAR gamma, pubmed-meshheading:18344626-Regional Blood Flow, pubmed-meshheading:18344626-Vasculitis
pubmed:year
2007
pubmed:articleTitle
Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.
pubmed:affiliation
Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
pubmed:publicationType
Journal Article, Clinical Trial